ICD-10 Coding for Diffuse Large B-Cell Lymphoma(C83.3, C83.33, C83.39)
Comprehensive guide to ICD-10 coding for diffuse large B-cell lymphoma, including primary, ancillary, and differential codes, documentation requirements, and common pitfalls.
Complete code families applicable to Diffuse Large B-Cell Lymphoma
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C83.3 | Diffuse large B-cell lymphoma | Use for confirmed cases of DLBCL with specified site. |
|
| C83.39 | Diffuse large B-cell lymphoma, extranodal and solid organ sites | Use when DLBCL is confirmed in extranodal sites. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutDiffuse Large B-Cell Lymphoma
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Diffuse Large B-Cell Lymphoma.
Failing to specify lymphoma site
Impact
Clinical: Impacts treatment decisions., Regulatory: Non-compliance with coding standards., Financial: Potential for incorrect billing.
Mitigation
Review pathology reports for site details, Educate staff on documentation standards
Misclassifying DLBCL as a secondary neoplasm
Impact
Reimbursement: Incorrect DRG assignment leading to reimbursement issues., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation
Use C83.39 for extranodal involvement instead of secondary site codes.
Site specification
Impact
Lack of site documentation can lead to audit findings.
Mitigation
Ensure all documentation includes specific site details.